Andrew Simms, MD
Infectious Disease · Omaha, NENPI 1124518030
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,241 of the $1,391 with a category attached, or 89.2%. It is spread thinly across 13 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,052 and has fallen 87.0% since, to $137 in 2025.
Across 48 payments — averaging $28.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$227
- Merck$191
- Melinta Therapeutics, LLC$185
- Gilead$181
- Viiv Healthcare Company$137
- Aimmune Therapeutics, Inc.$123
- plus $346 from 7 others
What the payments were for
- Food & beverage$1,24189%
- Education$15011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 6 | $227 |
| Merck | 10 | $191 |
| Melinta Therapeutics, LLC | 5 | $185 |
| Gilead | 2 | $181 |
| Viiv Healthcare Company | 5 | $137 |
| Aimmune Therapeutics, Inc. | 2 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $121 |
| Paratek Pharmaceuticals, Inc. | 3 | $57 |
| AbbVie | 3 | $51 |
| Shionogi Inc | 2 | $39 |
| CSL Behring | 1 | $34 |
| Insmed, Inc. | 2 | $30 |
| Pharming Healthcare, Inc. | 1 | $14 |
How this compares
$1,391 in reported general payments places this provider in the 70th percentile of 55 infectious disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErtapenemErtapenem Sodium | 14 | $5,804 |
| Methenamine Hippurate | 25 | $1,436 |
| Cefazolin Sodium | 20 | $848 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 28 | $609 |
| Cefadroxil | 22 | $253 |
| Doxycycline Hyclate | 14 | $186 |
| Levofloxacin | 11 | $105 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Omaha
- Rudolf KotulaOmaha$221K
- Marvin BittnerOmaha$100K
- Mark RuppOmaha$76K
- Trevor VanschooneveldOmaha$56K
- Nada FadulOmaha$26K
- Alison FreifeldOmaha$15K
- Amir GholamiOmaha$12K
- Andre KalilOmaha$11K
- Kelly CawcuttOmaha$11K
- Diana FlorescuOmaha$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.